Kenvue
Rujukan

↑  "Kenvue Inc. Registration Statement (Form S-1)". U.S. Securities and Exchange Commission. April 24, 2023.
1 2 3 4 5 6 7 8  Chapman, Michelle; Murphy, Tom (November 12, 2021). "Johnson & Johnson to split into two, aim for faster growth". Associated Press. Diakses tanggal May 7, 2023.
1 2  Kenvue Inc. (24 July 2023). "Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement". Business Wire (English).
↑  "Kenvue Showcases Tylenol Precise Cream, First Launch Since IPO". MMR. 40 (10): 18. 2023-09-11.
↑  Altman, Michael; Atasu, Atalay; Özkaya, Evren (2023-10-18). "How Kenvue De-Risked Its Supply Chain". Harvard Business Review Digital Articles: 1–8.
1 2  Kenvue Inc. (5 April 2023). "Kenvue to Begin Trading on the New York Stock Exchange". Business Wire (English).
1 2  Lipschultz, Bailey (2023-06-06). "Tylenol Maker Kenvue Goes From Sure Bet to Question Mark After Year's Biggest IPO". Bloomberg.com: N.PAG.
↑  "J&J Spinoff Kenvue Locating HQ in Summit", New Jersey Business Magazine, May 1, 2023. Accessed August 29, 2023. "Kenvue, the multibillion-dollar spinoff of Johnson & Johnson’s consumer health business, has chosen to locate its global headquarters in Summit.... Kenvue's product portfolio includes well known products Tylenol, Neutrogena, Listerine and Band-Aid, and the spinoff marks the largest restructuring in Johnson & Johnson's 135-year history.... Currently located in Skillman, Kenvue will slowly make a transition to the Summit East campus."
1 2 3 4 5 6 7 8  Robbins, Rebecca; de la Merced, Michael J. (November 12, 2021). "Johnson & Johnson, iconic company under pressure, plans to split in two". The New York Times. Diakses tanggal May 7, 2023.
1 2 3 4  Sorkin, Andrew Ross (January 23, 2009). "Pfizer said to be closing in on deal for Wyeth". The New York Times. Diakses tanggal May 8, 2023.
1 2 3 4 5  Saul, Stephanie (June 27, 2006). "Johnson & Johnson buys Pfizer unit for $16.6 billion". The New York Times. Diakses tanggal May 8, 2023.
↑  Hall, Jessica; Krauskopf, Lewis (January 25, 2009). "Pfizer to buy Wyeth for $68 billion". Reuters. Diakses tanggal May 8, 2023.
↑  Sorkin, Andrew Ross; Wilson, Duff (January 26, 2009). "Pfizer to acquire Wyeth for $68 billion". The New York Times. Diakses tanggal May 8, 2023.
1 2  "Form S-1, Amendment No. 4 (Kenvue, Inc.)". U.S. Securities and Exchange Commission. April 24, 2023. Diarsipkan dari versi asli tanggal May 7, 2023. Diakses tanggal May 8, 2023. We were incorporated in Delaware on February 23, 2022 in connection with the Separation and were formed to ultimately hold, directly or indirectly, and conduct certain operational activities in anticipation of the planned separation of, the Consumer Health Business. Prior to the completion of this offering, we are a wholly owned subsidiary of Johnson & Johnson and all of our outstanding shares of common stock are owned by Johnson & Johnson. Our principal executive offices are located [in] Skillman, NJ 08558.  Parameter |url-status= yang tidak diketahui akan diabaikan (bantuan)
↑  "Form S-1 (JNTL, Inc.)". U.S. Securities and Exchange Commission. August 30, 2022. Diarsipkan dari versi asli tanggal May 8, 2023. Diakses tanggal May 8, 2023.  Parameter |url-status= yang tidak diketahui akan diabaikan (bantuan)
1 2 3 4 5 6  Meyersohn, Nathaniel (September 29, 2022). "Band-Aids and Tylenol will have a new name on their packages". CNN Business. Diakses tanggal May 7, 2023.
↑  Satija, Bhanvi (January 4, 2023). "J&J's consumer health unit Kenvue files for IPO, moving closer to spin-off". Reuters. Diakses tanggal May 7, 2023.
↑  "J&J's Kenvue consumer health business prepares for stock IPO". Associated Press. April 25, 2023. Diakses tanggal May 7, 2023.
1 2 3 4 5 6  Nathan-Kazis, Josh. "Kenvue Stock Jumps in IPO of Former J&J Consumer-Health Business". Barron's. Dow Jones & Company. Diakses tanggal 16 May 2023. (perlu berlangganan)
↑  Singer, Drew; Patton, Leslie (May 4, 2023). "Maker of Tylenol, Band-Aid climbs in debut after biggest U.S. IPO since 2021". Bloomberg News. Diakses tanggal May 7, 2023.
↑  Saini, Manya; Satija, Bhanvi (May 4, 2023). "J&J's Kenvue eyes $47 billion valuation in biggest U.S. IPO since 2021". Reuters. Diakses tanggal May 7, 2023.
↑  Kenvue Inc. (5 August 2023). "Kenvue Announces Closing of Initial Public Offering". Business Wire (English).
↑  Baker, Liana (2023-05-03). "J&J's Kenvue Prices IPO at $22 Per Share". Bloomberg.com: N.PAG.
1 2 3 4  Megaw, Nicholas; Smyth, Jamie (May 4, 2023). "Johnson & Johnson consumer arm's shares jump in biggest U.S. IPO since 2021". Financial Times. Diakses tanggal May 7, 2023.
↑  Primack, Dan (May 4, 2023). "J&J's Kenvue rallies out of the gate following IPO". Axios. Diakses tanggal May 7, 2023.
↑  "johnson & Johnson Launches exchange off for the Separation of Kenvue".
↑  "J&J offers exchange for Kenvue shares". Dow Theory Forecasts. 79 (33): 1. 2023-08-14.
↑  "Constituent Change Announced for the S&P 500 Dividend Aristocrats Index" (PDF). S&P Dow Jones Indices. August 22, 2023.
1 2  Constantino, Annika Kim (May 5, 2023). "Kenvue CEO looks to brand, product innovation to drive growth after IPO". CNBC. Diakses tanggal May 7, 2023.
1 2  PR Newswire (2023-10-29). "Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Kenvue Inc: KESSLER-TOPAZ-lawsuit". PR Newswire US.
1 2  PR Newswire (2023-11-07). "Kessler Topaz Meltzer & Check, LLP Reminds Kenvue Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm: KTMC-investigation". PR Newswire US.
1 2  PR Newswire (2023-11-03). "KENVUE SHAREHOLDER ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kenvue To Contact Him Directly To Discuss Their Options: FARUQI&FARUQI-KVUE". PR Newswire US.
↑  PR Newswire (2023-10-30). "SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Kenvue Investors of a Lead Plaintiff Deadline of December 8, 2023: VINCENT-WONG-lawsuit". PR Newswire US.